Treatment of rheumatoid arthritis with interleukin 1 receptor antagonist.
作者信息
Bresnihan B
机构信息
Department of Rheumatology, St Vincents University Hospital, Dublin 4, Ireland.
出版信息
Ann Rheum Dis. 1999 Nov;58 Suppl 1(Suppl 1):I96-8. doi: 10.1136/ard.58.2008.i96.
Abstract
摘要
相似文献
1
Treatment of rheumatoid arthritis with interleukin 1 receptor antagonist.
Ann Rheum Dis. 1999 Nov;58 Suppl 1(Suppl 1):I96-8. doi: 10.1136/ard.58.2008.i96.
2
Anakinra shows promise for treating patients with rheumatoid arthritis.
J Am Pharm Assoc (Wash). 2002 Jul-Aug;42(4):660-2. doi: 10.1331/108658002763029661.
3
The trials of anakinra.
Lancet. 2004;364(9437):827-8. doi: 10.1016/S0140-6736(04)16999-7.
4
Anakinra (interleukin-1 receptor antagonist) has positive effects on function and quality of life in patients with rheumatoid arthritis.
Adv Ther. 2006 Mar-Apr;23(2):208-17. doi: 10.1007/BF02850127.
5
Effects of anakinra on clinical and radiological outcomes in rheumatoid arthritis.
Ann Rheum Dis. 2002 Nov;61 Suppl 2(Suppl 2):ii74-7. doi: 10.1136/ard.61.suppl_2.ii74.
6
The many worlds of reducing interleukin-1.
Arthritis Rheum. 2005 Jul;52(7):1960-7. doi: 10.1002/art.21107.
7
From the Food and Drug Administration.
JAMA. 2002 Jan 2;287(1):33.
8
[Interleukin-1 receptor antagonists in the treatment rheumatoid arthritis].
Przegl Lek. 2002;59(11):916-8.
9
[The safety of interleukin-1 receptor antagonist (anakinra) in the treatment of rheumatoid arthritis].
Reumatismo. 2004 Jan-Mar;56(1 Suppl 1):74-9. doi: 10.4081/reumatismo.2004.1s.74.
10
[Anakinra for therapy of rheumatoid arthritis].
Nihon Rinsho. 2005 Jan;63 Suppl 1:534-7.
引用本文的文献
1
A genome-engineered bioartificial implant for autoregulated anticytokine drug delivery.
Sci Adv. 2021 Sep 3;7(36):eabj1414. doi: 10.1126/sciadv.abj1414. Epub 2021 Sep 1.
2
IL-1RA suppresses esophageal cancer cell growth by blocking IL-1α.
J Clin Lab Anal. 2019 Jul;33(6):e22903. doi: 10.1002/jcla.22903. Epub 2019 May 17.
3
Interleukin-1 receptor antagonist inhibits angiogenesis in gastric cancer.
Int J Clin Oncol. 2018 Aug;23(4):659-670. doi: 10.1007/s10147-018-1242-2. Epub 2018 Jan 17.
4
Therapeutic potential of GW501516 and the role of Peroxisome proliferator-activated receptor β/δ and B-cell lymphoma 6 in inflammatory signaling in human pancreatic cancer cells.
Biochem Biophys Rep. 2016 Nov 4;8:395-402. doi: 10.1016/j.bbrep.2016.10.014. eCollection 2016 Dec.
5
Association of IL-1A and IL-1B polymorphisms with ankylosing spondylitis among the Chinese Han population: a case-control study.
Oncotarget. 2017 Apr 25;8(17):28278-28284. doi: 10.18632/oncotarget.16004.
6
Immune-related gene polymorphisms in pulmonary diseases.
Toxicology. 2017 May 15;383:24-39. doi: 10.1016/j.tox.2017.03.020. Epub 2017 Mar 30.
7
Olfactory ecto-mesenchymal stem cells possess immunoregulatory function and suppress autoimmune arthritis.
Cell Mol Immunol. 2016 May;13(3):401-8. doi: 10.1038/cmi.2015.82. Epub 2015 Sep 21.
8
Analgesic, anti-inflammatory and anti-pyretic activities of Caesalpinia decapetala.
Bioimpacts. 2014;4(1):43-8. doi: 10.5681/bi.2014.013. Epub 2014 Apr 10.
9
A computer simulation approach to assessing therapeutic intervention points for the prevention of cytokine-induced cartilage breakdown.
Arthritis Rheumatol. 2014 Apr;66(4):979-89. doi: 10.1002/art.38297.
10
Sustained delivery of IL-1Ra from pluronic F127-based thermosensitive gel prolongs its therapeutic potentials.
Pharm Res. 2012 Dec;29(12):3475-85. doi: 10.1007/s11095-012-0843-0. Epub 2012 Aug 21.
本文引用的文献
1
Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data.
Arthritis Rheum. 1999 Mar;42(3):498-506. doi: 10.1002/1529-0131(199904)42:3<498::AID-ANR15>3.0.CO;2-A.
2
Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.
Arthritis Rheum. 1998 Dec;41(12):2196-204. doi: 10.1002/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO;2-2.
3
Lessons for joint destruction from animal models.
Curr Opin Rheumatol. 1997 May;9(3):221-8. doi: 10.1097/00002281-199705000-00008.
4
Prevention of murine collagen-induced arthritis in the knee and ipsilateral paw by local expression of human interleukin-1 receptor antagonist protein in the knee.
Arthritis Rheum. 1997 May;40(5):893-900. doi: 10.1002/art.1780400517.
5
Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis.
Arthritis Rheum. 1996 Feb;39(2):257-65. doi: 10.1002/art.1780390212.
6
Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group.
Arthritis Rheum. 1996 Jul;39(7):1092-101. doi: 10.1002/art.1780390704.
7
Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra.
Arthritis Rheum. 1996 May;39(5):797-809. doi: 10.1002/art.1780390513.
8
Biologic basis for interleukin-1 in disease.
Blood. 1996 Mar 15;87(6):2095-147.
9
The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials.
Arthritis Rheum. 1993 Jun;36(6):729-40. doi: 10.1002/art.1780360601.
10
Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis.
Arthritis Rheum. 1995 Feb;38(2):151-60. doi: 10.1002/art.1780380202.
Zotero 插件